Gliomas are intrinsic brain tumours thought to arise from neuroglial progenitor cells that are highly infiltrative, often angiogenic and essentially incurable. Glioblastoma, the most common variant, is defined as a glial tumour with certain histological characteristics including necrosis and vascular proliferation. Moreover, there are typical molecular features found in subsets of glioblastomas, such as gain of chromosome 7 and loss of chromosome 10, EGFR amplifications and telomerase reverse transcriptase promoter mutations. The vast majority of glioblastomas harbour genetic alterations in the PI3K, retinoblastoma and/or p53 signalling pathways 1 . The standard of care for patients with newly diagnosed glioblastoma consists of neurosurgical resection, as safely feasible, followed by involved field radiotherapy with concomitant and maintenance temozolomide chemotherapy. At recurrence, second surgery and re-irradiation are both options for some patients, but most will receive second-line systemic chemotherapy with either alkylating agents, such as lomustine, or bevacizumab 2 . The median survival duration of patients receiving these treatments remains approximately 1 year according to registry-based epidemiological studies. Numerous attempts To date, demonstrations of clinical benefit from immune-checkpoint inhibition in patients with glioblastoma have been limited to individual patients whose tumours have excessively high mutational burdens owing to mismatch repair deficiencies.
This scenario provided the framework for three recent studies published in Nature Medicine, in which investigators attempted to identify predictors of benefit from immunecheckpoint inhibition and whether these agents have any measurable level of biological activity in patients with glioblastomas [6] [7] [8] . Zhao and colleagues 6 attempted to distinguish responders to immune-checkpoint inhibition from nonresponders. Following genomic and transcriptomic analyses, these investigators proposed that PTEN mutations are linked with immunosuppressive gene-expression signatures and resistance to immune-checkpoint inhibition, whereas tumours from responders were found to harbour MAPK pathway alterations.
Schalper and colleagues 7 adopted a pharmacodynamic approach, often referred to as a phase 0 study, in which they administered a single presurgical (at 2 weeks ± 3 days before surgery) dose of nivolumab to 30 patients, the majority of whom (n = 27) had recurrent disease. The evolution of the tumour microenvironment of these patients was then compared to that of a reference cohort that was not exposed to immune-checkpoint inhibitors. The authors reported that nivolumab induced increased expression of several chemokine transcripts, promoted immune-cell infiltration and augmented T cell receptor clonal diversity in the tumour-infiltrating T cell compartment.
Data from these two studies 6, 7 seem to demonstrate that the glioblastoma microenvironment is indeed not completely refractory to the immunomodulatory effects of immune-checkpoint inhibition. However, one might still argue that clinical benefit from immune-checkpoint inhibition, as defined by to improve these outcomes by adding novel systemic agents to the standard of care in the first-line setting, including a phase III trial exploring the efficacy of a vaccine targeting EGFR variant III, which features the loss of exons 2-7, have failed to improve overall survival 3 . Furthermore, the first phase III trial involving immune-checkpoint inhibitors in neuro-oncology, CheckMate 143 (NCT02017717), in which the efficacy of nivolumab was compared with that of bevacizumab in patients with glioblastoma at first relapse, did not demonstrate superiority of nivolumab in the overall patient population 4 . The results of this trial are of continued interest because interpretation of the outcomes is dependent on whether bevacizumab alone is considered an active agent in this setting -this has never been formally tested. Furthermore, ongoing subgroup analyses of data from this trial might aid in identifying patients who are more likely, or less likely, to derive benefit from either nivolumab or bevacizumab. However, the recognition of glioblastoma as the paradigmatic lymphocyte-depleted cancer 5 has further dampened the great expectations that immunotherapy might provide a therapeutic breakthrough in this disease.
C N S C A N C E R Immunotherapy for glioblastoma: quo vadis?
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Glioblastoma remains essentially incurable, and new therapeutic approaches are urgently needed. Now, the findings of three serial tissue-based studies suggest that immune-checkpoint inhibition can modify the glioblastoma microenvironment. Following these encouraging observations, the results of two phase III trials of immune-checkpoint inhibition in newly diagnosed glioblastoma, with larger cohorts of patients, are eagerly anticipated. 
NEws & VIEws
Nature reviews | CliniCal OnCOlOgy …the glioblastoma microenvironment is indeed not completely refractory to the immunomodulatory effects of immune-checkpoint inhibition Zhao et al. 6 , remains controversial and that the historical control group presented by Schalper et al. 7 leaves doubts as to whether or not the effects on the microenvironment are specifically mediated by nivolumab; moreover, these studies, by design, do not provide evidence of clinical benefit. These various shortcomings are largely overcome by the data reported by Cloughesy et al. 8 , who conducted a small, randomized phase 0/2 study in which patients with recurrent glioblastoma who were considered candidates for second surgery received pembrolizumab. Patients were randomly assigned to receive either adjuvant pembrolizumab alone or a single presurgical dose of pembrolizumab (14 ± 5 days before surgery) followed by adjuvant pembro lizumab. When compared with the adjuvant only group, presurgical pembrolizumab resulted in the induction of a T cell-related and IFNγ-related gene expression signature with clonal T cell expansion, demonstrating that the glioblastoma micro environment can potentially be modified even by a single dose of pembrolizumab. Unexpectedly, patients who had been randomly assigned to receive a single presurgical dose of pembrolizumab also had prolonged overall survival durations (13.7 months versus 7.5 months, HR 0.43, 95% CI 0.20-0.90; P = 0.03). Imbalan ces in patient characteristics, if they had any effect, would have favoured the adjuvant only group because 69% of patients in this group had MGMT-promoter methylation as opposed to 38% in the presurgical group. Admittedly, this was a small study (n = 32) in which overall survival was a secondary or exploratory end point. Yet, this observation of significantly longer overall survival after a single presurgical dose of pembrolizumab encourages speculation regarding whether the iatrogenic trauma of surgery facilitates a durable immune res ponse once the immunosuppressive properties of glioblastoma are counterbalanced by immune-checkpoint inhibition. Future studies with similar designs, potentially even involving combinations of immune-checkpoint inhibitors, are likely to follow.
Meanwhile, two phase III randomized prospective trials exploring the activity, safety and tolerability of nivolumab in patients with newly diagnosed glioblastoma have completed patient enrolment, although data are yet to be analysed. CheckMate 498 (NCT02617589) took advantage of the emerging concept that temozolomide can be omitted from the first-line treatment of patients with MGMTpromoter-unmethylated glioblastoma owing to only marginal benefits of this approach in this patient population 9 . Accordingly, CheckMate 498 is designed to compare the efficacy of radio therapy plus nivolumab with that of radiotherapy plus temozolomide as the current standard of care in these patients. The companion trial, CheckMate 548 (NCT02667587), is a placebo-controlled trial designed to explore the efficacy of the addition of nivolumab to standard-of-care chemoradiotherapy in patients with MGMT-promotermethylated glioblastoma. A concern remains that the combination of a cytotoxic agent with an immune-checkpoint inhibitor might abrogate any activation of the T cell compartment and could thus inhibit any relevant anti tumour activity. However, data from animal models indicate that part of the antitumour activity of temozolomide might indeed be immunemediated 10 and chronic exposure to temozolomide might also deplete the regulatory T cell pool. These considerations, plus the assumption, as yet unproven, that prolonged treatment with temozolomide steadily increases the tumour mutational burden of patients with newly diagnosed MGMT-promotermethylated glioblastoma, support the notion that CheckMate 548 may provide the first positive phase III data from a trial involving immuno therapy in patients with brain tumours. The community will know soon. 
N e w s & V i e w s
Breast cancer has been the subject of many studies aimed at the identification of prognostic markers and predictors of response to treatment (Table 1) . Some of this work is several decades old, including the early discovery of the importance of regional lymph node involvement and tumour size, which remain the most powerful pair of prognostic markers 1 . These markers have been combined with tumour grade, patient age and treatment type to create the Clinical Treatment Score (CTS), which has prognostic value for B R E A S T C A N C E R Predicting late recurrence in ER-positive breast cancer
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Identification of factors predicting recurrence of breast cancer is a long-standing goal, ranging from classical clinicopathological factors through to immunohistochemical assays of receptor levels and, more recently, the expression levels of several genes. A new paper now explores novel expression markers, especially for late recurrence of oestrogen receptor-positive breast cancer.
